SAP: Negative read across from Workday's Q1 FY16 results
NEUTRAL, Fair Value EUR68 (+1%)
Alten: Feedback from Paris investor roadshow
NEUTRAL, Fair Value EUR42 (-4%)
Richemont: Price adjustments in dollar zone explain the sales decline in April
BUY, Fair Value CHF100 (+16%)
AstraZeneca: Amgen leaves AstraZeneca alone with brodalumab
NEUTRAL, Fair Value 4830p vs. 4860p (+8%)
Pernod Ricard: Martell enjoys growth opportunities
BUY-Top Picks, Fair Value EUR129 (+15%)